List of Tables
Table 1. Global Monoclonal Antibodies for Primary Hypercholesterolemia Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Monoclonal Antibodies for Primary Hypercholesterolemia Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Monoclonal Antibodies for Primary Hypercholesterolemia Market Competitive Situation by Manufacturers in 2025
Table 4. Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales (Units) of Key Manufacturers (2021–2026)
Table 5. Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Monoclonal Antibodies for Primary Hypercholesterolemia Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Monoclonal Antibodies for Primary Hypercholesterolemia, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Monoclonal Antibodies for Primary Hypercholesterolemia, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Monoclonal Antibodies for Primary Hypercholesterolemia, Product Types and Applications
Table 12. Global Key Manufacturers of Monoclonal Antibodies for Primary Hypercholesterolemia, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Monoclonal Antibodies for Primary Hypercholesterolemia Companies by Tier (Tier 1, Tier 2, Tier 3), based on Monoclonal Antibodies for Primary Hypercholesterolemia Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Monoclonal Antibodies for Primary Hypercholesterolemia Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Region (Units), 2021–2026
Table 18. Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales Market Share by Region (2021–2026)
Table 19. Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Region (Units), 2027–2032
Table 20. Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales Market Share by Region (2027–2032)
Table 21. Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Region (US$ Million), 2021–2026
Table 22. Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Market Share by Region (2021–2026)
Table 23. Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Region (US$ Million), 2027–2032
Table 24. Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Market Share by Region (2027–2032)
Table 25. North America Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Country (Units), 2021–2026
Table 27. North America Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Country (Units), 2027–2032
Table 28. North America Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Country (US$ Million), 2021–2026
Table 29. North America Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Country (Units), 2021–2026
Table 32. Europe Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Country (Units), 2027–2032
Table 33. Europe Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Region (Units), 2021–2026
Table 37. Asia Pacific Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Region (Units), 2027–2032
Table 38. Asia Pacific Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Country (Units), 2021–2026
Table 42. Latin America Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Country (Units), 2027–2032
Table 43. Latin America Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Country (Units), 2021–2026
Table 47. Middle East and Africa Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Country (Units), 2027–2032
Table 48. Middle East and Africa Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Country (US$ Million), 2027–2032
Table 50. Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales (Units) by Type (2021–2026)
Table 51. Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales (Units) by Type (2027–2032)
Table 52. Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales Market Share by Type (2021–2026)
Table 53. Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales Market Share by Type (2027–2032)
Table 54. Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Market Share by Type (2021–2026)
Table 57. Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Market Share by Type (2027–2032)
Table 58. Global Monoclonal Antibodies for Primary Hypercholesterolemia Price (US$/Unit) by Type (2021–2026)
Table 59. Global Monoclonal Antibodies for Primary Hypercholesterolemia Price (US$/Unit) by Type (2027–2032)
Table 60. Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales (Units) by Application (2021–2026)
Table 61. Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales (Units) by Application (2027–2032)
Table 62. Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales Market Share by Application (2021–2026)
Table 63. Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales Market Share by Application (2027–2032)
Table 64. Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Market Share by Application (2021–2026)
Table 67. Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Market Share by Application (2027–2032)
Table 68. Global Monoclonal Antibodies for Primary Hypercholesterolemia Price (US$/Unit) by Application (2021–2026)
Table 69. Global Monoclonal Antibodies for Primary Hypercholesterolemia Price (US$/Unit) by Application (2027–2032)
Table 70. Amgen, Inc. Company Information
Table 71. Amgen, Inc. Description and Business Overview
Table 72. Amgen, Inc. Monoclonal Antibodies for Primary Hypercholesterolemia Sales (Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Amgen, Inc. Monoclonal Antibodies for Primary Hypercholesterolemia Product
Table 74. Amgen, Inc. Recent Developments/Updates
Table 75. Sanofi SA Company Information
Table 76. Sanofi SA Description and Business Overview
Table 77. Sanofi SA Monoclonal Antibodies for Primary Hypercholesterolemia Sales (Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Sanofi SA Monoclonal Antibodies for Primary Hypercholesterolemia Product
Table 79. Sanofi SA Recent Developments/Updates
Table 80. Innovent Biologics, Inc Company Information
Table 81. Innovent Biologics, Inc Description and Business Overview
Table 82. Innovent Biologics, Inc Monoclonal Antibodies for Primary Hypercholesterolemia Sales (Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Innovent Biologics, Inc Monoclonal Antibodies for Primary Hypercholesterolemia Product
Table 84. Innovent Biologics, Inc Recent Developments/Updates
Table 85. Akeso Biopharma Co., Ltd Company Information
Table 86. Akeso Biopharma Co., Ltd Description and Business Overview
Table 87. Akeso Biopharma Co., Ltd Monoclonal Antibodies for Primary Hypercholesterolemia Sales (Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Akeso Biopharma Co., Ltd Monoclonal Antibodies for Primary Hypercholesterolemia Product
Table 89. Akeso Biopharma Co., Ltd Recent Developments/Updates
Table 90. Shanghai Junshi Biosciences Co., Ltd Company Information
Table 91. Shanghai Junshi Biosciences Co., Ltd Description and Business Overview
Table 92. Shanghai Junshi Biosciences Co., Ltd Monoclonal Antibodies for Primary Hypercholesterolemia Sales (Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Shanghai Junshi Biosciences Co., Ltd Monoclonal Antibodies for Primary Hypercholesterolemia Product
Table 94. Shanghai Junshi Biosciences Co., Ltd Recent Developments/Updates
Table 95. Key Raw Materials Lists
Table 96. Raw Materials Key Suppliers Lists
Table 97. Monoclonal Antibodies for Primary Hypercholesterolemia Distributors List
Table 98. Monoclonal Antibodies for Primary Hypercholesterolemia Customers List
Table 99. Monoclonal Antibodies for Primary Hypercholesterolemia Market Trends
Table 100. Monoclonal Antibodies for Primary Hypercholesterolemia Market Drivers
Table 101. Monoclonal Antibodies for Primary Hypercholesterolemia Market Challenges
Table 102. Monoclonal Antibodies for Primary Hypercholesterolemia Market Restraints
Table 103. Research Programs/Design for This Report
Table 104. Key Data Information from Secondary Sources
Table 105. Key Data Information from Primary Sources
Table 106. Authors List of This Report
List of Figures
Figure 1. Product Picture of Monoclonal Antibodies for Primary Hypercholesterolemia
Figure 2. Global Monoclonal Antibodies for Primary Hypercholesterolemia Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Monoclonal Antibodies for Primary Hypercholesterolemia Market Share by Type: 2025 & 2032
Figure 4. 140 mg/mL Product Picture
Figure 5. 150 mg/mL Product Picture
Figure 6. 300 mg/mL Product Picture
Figure 7. Global Monoclonal Antibodies for Primary Hypercholesterolemia Market Value by Application (US$ Million), 2021–2032
Figure 8. Global Monoclonal Antibodies for Primary Hypercholesterolemia Market Share by Application: 2025 & 2032
Figure 9. Hospital
Figure 10. Clinic
Figure 11. Others
Figure 12. Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 13. Global Monoclonal Antibodies for Primary Hypercholesterolemia Market Size (US$ Million), 2021–2032
Figure 14. Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales (Units), 2021–2032
Figure 15. Global Monoclonal Antibodies for Primary Hypercholesterolemia Average Price (US$/Unit), 2021–2032
Figure 16. Monoclonal Antibodies for Primary Hypercholesterolemia Report Years Considered
Figure 17. Monoclonal Antibodies for Primary Hypercholesterolemia Sales Share by Manufacturers in 2025
Figure 18. Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Share by Manufacturers in 2025
Figure 19. Top 5 and Top 10 Global Monoclonal Antibodies for Primary Hypercholesterolemia Players: Market Share by Revenue in Monoclonal Antibodies for Primary Hypercholesterolemia in 2025
Figure 20. Monoclonal Antibodies for Primary Hypercholesterolemia Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 21. Global Monoclonal Antibodies for Primary Hypercholesterolemia Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 22. North America Monoclonal Antibodies for Primary Hypercholesterolemia Sales Market Share by Country (2021–2032)
Figure 23. North America Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Market Share by Country (2021–2032)
Figure 24. United States Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Canada Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Europe Monoclonal Antibodies for Primary Hypercholesterolemia Sales Market Share by Country (2021–2032)
Figure 27. Europe Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Market Share by Country (2021–2032)
Figure 28. Germany Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. France Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. U.K. Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Italy Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Russia Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Asia Pacific Monoclonal Antibodies for Primary Hypercholesterolemia Sales Market Share by Region (2021–2032)
Figure 34. Asia Pacific Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Market Share by Region (2021–2032)
Figure 35. China Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Japan Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. South Korea Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. India Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Australia Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. China Taiwan Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Southeast Asia Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Latin America Monoclonal Antibodies for Primary Hypercholesterolemia Sales Market Share by Country (2021–2032)
Figure 43. Latin America Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Market Share by Country (2021–2032)
Figure 44. Mexico Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Brazil Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Argentina Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Colombia Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Middle East and Africa Monoclonal Antibodies for Primary Hypercholesterolemia Sales Market Share by Country (2021–2032)
Figure 49. Middle East and Africa Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Market Share by Country (2021–2032)
Figure 50. Turkey Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Saudi Arabia Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. UAE Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Global Sales Market Share of Monoclonal Antibodies for Primary Hypercholesterolemia by Type (2021–2032)
Figure 54. Global Revenue Market Share of Monoclonal Antibodies for Primary Hypercholesterolemia by Type (2021–2032)
Figure 55. Global Monoclonal Antibodies for Primary Hypercholesterolemia Price (US$/Unit) by Type (2021–2032)
Figure 56. Global Sales Market Share of Monoclonal Antibodies for Primary Hypercholesterolemia by Application (2021–2032)
Figure 57. Global Revenue Market Share of Monoclonal Antibodies for Primary Hypercholesterolemia by Application (2021–2032)
Figure 58. Global Monoclonal Antibodies for Primary Hypercholesterolemia Price (US$/Unit) by Application (2021–2032)
Figure 59. Monoclonal Antibodies for Primary Hypercholesterolemia Value Chain
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
